Plasmid-normalized quantification of relative mitochondrial DNA copy number

Federica Fazzini1, Bernd Schöpf1, Michael Blatzer1,2,3, Stefan Coassin1, Andrew A. Hicks4, Florian Kronenberg1 & Liane Fendt1

Alterations of mitochondrial DNA (mtDNA) copy number have been associated with a wide variety of phenotypes and diseases. Unfortunately, the literature provides scarce methodical information about duplex targeting of nuclear and mtDNA that meets the quality criteria for qPCR. Therefore, we established a method for mtDNA copy number quantification using a quantitative PCR assay that allows for simultaneous targeting of a single copy nuclear gene (beta-2-microglobulin) and the t-RNALeu gene on the mtDNA. We include a plasmid containing both targets in order to normalize against differences in emission intensities of the fluorescent dyes Yakima Yellow and FAM. Applying the plasmid calibrator on an internal control reduced the intra-assay variability from 21% (uncorrected) to 7% (plasmid-corrected). Moreover, we noted that DNA samples isolated with different methods revealed different numbers of mtDNA copies, thus highlighting an important influence of the pre-analytical procedures. In summary, we developed a precise assay for mitochondrial copy number detection relative to nuclear DNA. Our method is applicable to comparative mitochondrial DNA copy number studies since the use of the dual insert plasmid allows correcting for the unequal emission intensities of the different fluorescent labels of the two targets.

Human mitochondrial DNA (mtDNA) is a small (approximately 16,568 base pair), circular and multi-copy genome. It incorporates 37 mitochondrial (mt) genes including 13 coding for essential components of the mitochondrial electron transport chain and of the ATP synthase complex, 22 for mitochondrial transfer RNAs and 2 for ribosomal RNAs1. The remaining mitochondrial genes are encoded in the two copies of nuclear DNA (nDNA). The number of mitochondria per cell varies constantly depending on the energy demands, oxidative stress and pathological conditions2. Each mitochondrion can contain 2–10 copies of mtDNA and up to 1000 mitochondria are present per cell3.

In recent years, the mitochondrial DNA copy number (mtDNA-CN) has been proposed to be a potential biomarker of mitochondrial dysfunction4 and studies targeting mitochondrial diversity have increased considerably. This is based on the rationale that the mitochondrial content reflects the energy demand of a cell and is disturbed by an imbalanced energy metabolism5. The ratio between mitochondrial and nuclear genomes (mt/nuc) is a suitable measure for the mtDNA content6. Several studies have examined the correlation between mtDNA-CN and diverse phenotypes and diseases. An increase of the mtDNA-CN relative to the nDNA is reported in a variety of disease states including acute kidney failure7, brain injury8, cancer risk9 and metabolic disorders10. A reduced mtDNA-CN has been observed in Parkinson’s disease11, tumour development and progression12 as well as aging13. Moreover, other studies claimed an increase of mtDNA-CN with age14 or a protective effect of higher mtDNA-CN against kidney disease15. Both positive and negative associations have been found regarding type 2 diabetes16,17 and breast cancer18,19.

As recently discussed in the literature, inaccuracies in the methodology for measuring mtDNA-CN might be, in part, responsible for the observed discrepant results5. Moreover, the mtDNA-CN measurement can be affected by different pre-analytical factors19,20 and reproducibility between different laboratories is challenging especially because the majority of the published studies do not describe their methods in detail.

1Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. 2Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria. 3Present address: Unité des Aspergillus, Institut Pasteur, Paris, France. 4Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy. Correspondence and requests for materials should be addressed to L.F. (email: Liane.Fendt@i-med.ac.at)

Received: 23 May 2018
Accepted: 2 October 2018
Published online: 18 October 2018
Quantitative real-time PCR (qPCR) is the current method of choice for mtDNA copy number quantification. The measurement can be carried out also by alternative methods such as next generation sequencing, microarrays and recently also droplet digital PCR. However, these three approaches are expensive and extremely laborious if applied in epidemiological studies with thousands of samples. Moreover, array-based and sequencing data-based methods are biased by the presence of “wave-like patterns” that can interfere with an accurate copy number variation detection and cannot be fully corrected bioinformatically.

The aim of this study was to establish a reliable method to quantify mtDNA-CN according to MIQE (Minimum Information for publication of Quantitative real-time PCR experiments) guidelines that can fulfill requirements for epidemiological studies: fast, automatable for high-throughput, cheap, simple to use and easy to analyze. Taking advantage of recent developments we designed a duplex qPCR-based method with two hydrolysis probes, targeting mtDNA and nuclear DNA, that allows a minimization of the well-to-well variability that occurs when comparing multiple singleplex reactions. In addition, we constructed a dual insert plasmid containing segments of mtDNA and nuclear DNA to correct for inter-assay variability. Furthermore, we investigated the impact of DNA isolation methods on the quantification results of mtDNA-CN.

Methods

Samples. All DNA samples were extracted from EDTA blood. Study participants provided informed consent. The extraction methods are described below.

EDTA-blood was collected from:

1. Eighteen healthy donors from the Central Institute of Blood Transfusion and Immunology, Innsbruck, Austria. Blood samples were stored at −80°C before DNA extraction;
2. Four healthy donors. DNA was extracted immediately after blood collection;
3. 303 hemodialysis patients of the Family Heart and Kidney Study (FHKS). FHKS is an ongoing prospective multicentre cohort study that aims to investigate the genetic variability of selected candidate genes influencing atherosclerotic complication.
4. 176 patients of the German Chronic Kidney Disease (GCKD) study. GCKD is an ongoing prospective observational cohort study including patients with CKD of moderate severity. DNA was extracted from frozen EDTA-blood samples.

Ethical approval and informed consent. The examination protocol of the FHKS study was approved by the Ethics Committee of the Medical University of Innsbruck. The GCKD study was approved by the Ethics Committees of all participating institutions (Friedrich-Alexander-University Erlangen-Nuremberg, Medical Faculty of the Rheinisch-Westfälische Technische Hochschule Aachen, Charité—University Medicine Berlin, Medical Center—University of Freiburg, Medizinische Hochschule Hannover, Medical Faculty of the University of Heidelberg, Friedrich-Schiller-University Jena, Medical Faculty of the Ludwig-Maximilians-University Munich, Medical Faculty of the University of Würzburg). All methods were carried out in accordance with the approved guidelines and the Declaration of Helsinki. Written informed consent was obtained from each study participant.

DNA extraction methods. The impact of DNA extraction methods on the measurement of the mtDNA-CN was evaluated using four different methods.

- Magnetic beads-based extraction. The EZ1 DNA Blood 200 µl kit (Qiagen Hilden, Germany) and the EZ1 DNA Tissue kit were selected as representatives of the automated kits using silica-coated magnetic beads for extraction. DNA extraction was performed using BioRobot EZ1 Advanced (Qiagen, Hilden, Germany) in sample set (1), (2) and (3) described above. The EZ1 DNA Tissue kit was used to perform a comparison between different lysis buffers. We added an initial erythrocyte lysis step to the original protocol using RBC Lysis Solution (Qiagen, Hilden, Germany). After centrifugation (2 min at 2000 × g) the white blood cell pellet obtained was resuspended using two different buffers: the G2 buffer included in the kit and a Pierce RIPA Buffer Lyse (Thermo Fisher Scientific, Waltham, MA, USA). Both buffers were used pure and supplemented with Proteinase K (at 1 mg/ml, Qiagen, Hilden, Germany). Different incubation times were applied to the DNA samples (15 min, 1 h, 3 h, 12 h, 24 h, 48 h and 72 h) before performing the DNA automated extraction. According to the kit instruction manual, G2 buffer lysis time was applied only for 3 h, 12 h, 24 h, 48 h and 72 h. Chemagic Magnetic Separation Module I (PerkinElmer Chemagen Technologie GmbH, Baesweiler, Germany) was used for the DNA extraction of GCKD samples (sample set 4).
- Manual salting out. The DNA was isolated from blood using two different kits: INVISORB Blood Universal Kit (Stratec Molecular, Berlin, Germany) for sample set (1) and (3) and PureGene (Qiagen, Hilden, Germany) for sample set (2). Genomic DNA was isolated from EDTA blood as recommended by the manufacturer. In brief, both protocols comprised a selective erythrocyte lysis, followed by a lysis of remaining cells with an optimized buffer system. Proteins were removed and DNA was recovered by precipitation with isopropanol. DNA was resuspended in the respective elution buffers provided by the kits.
- Phenol–chloroform–isoamyl alcohol extraction (PCI) was used in sample set (1). DNA extraction was performed as described in the previous paragraph but a phenol–chloroform–isoamyl alcohol purification step was introduced before the DNA precipitation step.
- Chelex 100 Resin (BioRad, Hercules, CA, USA) was used in sample set (2). Chelex is a resin binding cations like Mg++, which are essential for the activity of DNase. In brief, following the manufacturers protocol, cells
were incubated in Chelex solution without further washing steps. This method was chosen in order to get closer to the biological state of the cells and avoid unexpected losses due to washing or precipitation steps.

Purity (absorbance ratio at 260/280) and concentration of DNA samples were assessed using Tecan NanoQuant infinite M200 (Tecan Group Ltd., Mannefedorf, Switzerland).

In these comparative experiments, the measured values are expressed as means ± standard deviation.

**Duplex real-time PCR assay.** A duplex assay based on quantitative real-time polymerase chain reaction (qPCR) was established for measuring the amount of mtDNA-CN relative to the nuclear DNA. This assay allows for the simultaneous targeting of the mitochondrial tRNA\textsubscript{Leu} (108 bp) and the nuclear single copy gene beta-2-microglobulin, which is an ideal reference for blood cells\textsuperscript{11,32–34}. The mtDNA target sequence was chosen based on the absence of known phylogenetic polymorphism within the Caucasian population and with a MAF (minor allele frequency) <1% in the global population\textsuperscript{35}. The chosen region might incorporate the pathologic A3243G mutation present in 80% of MELAS patients which, however, has only a frequency of 1:10000 in the general population\textsuperscript{36}. The specificity of the primer pairs was confirmed in silico by Primer Blast\textsuperscript{37}. The potential amplification of nuclear insertions of mitochondrial origin (NUMTs) was excluded by deep sequencing of the amplicons using an Illumina MiSeq platform with a minimum coverage exceeding 80,000X. Inspecting the reads for low level admixture of potential NUMTs -specific variants was performed using the mtDNA-Server\textsuperscript{38}. The primer and probe sequences were modified from Bai et al.\textsuperscript{39}. In brief, a region of mtDNA-tRNA\textsubscript{Leu} was amplified using the forward primer 5′-CACCCAAGAACAGGGTTTGT and the reverse primer 5′-TGCCCATGGGATGTTGTTA; a region of beta-2-microglobulin (B2M) was amplified using the forward primer 5′-TGCTGTCCTCCATGTTGATG and the reverse primer: 5′-TCTCTGCTCCCCACTCTTAAGT. Probe sequences were: FAM-5′-TTACCGGGCTCTGCCATCT-BHQ1 and Yakima Yellow-5′-CAGGTTGCTCCACAGGTAGCTCAG-BHQ1 for mt-tRNA\textsubscript{Leu} and Yakima Yellow-5′-CAGGTTGCTCCACAGGTAGCTCAG-BHQ1 for beta-2-microglobulin. Primers and probes were synthesized by Microsynth AG, Balgach, Switzerland.

The quantitative PCR was performed on the Quantstudio 6 instrument (Thermo Fisher Scientific, Waltham, MA, USA) using the following conditions: 95°C for 3 minutes for initial polymerase activation, 40 cycles of 95°C for 15 sec and 60°C for 1 min. The robustness of the assay was tested using changing primer concentrations (300–600 nM) and annealing temperatures (60–62°C). PCR amplification was run in a 10 μl reaction consisting of: 5 μl Brilliant III Ultra-Fast qPCR Master Mix with low ROX (Agilent Technologies, Santa Clara, CA, USA), 1 μl mtDNA primers (300 nM each), 1 μl nDNA primers (600 nM each), 1 μl mtDNA probe (300 nM), 1 μl nDNA probe (300 nM) and 1 μl DNA (3–5 ng). Each sample was assayed in triplicate. We used different primer concentrations for the two targets due to amplification advantages of the more abundantly present one. By limiting the amount of mtDNA primers the reaction plateaus earlier and leaves sufficient dNTPs for the amplification of the less abundant target.

**Droplet digital PCR (ddPCR).** To validate our method also with another quantification approach, we measured 52 samples from sample set nr. 1 (see “Methods” section) with ddPCR. We obtained the best results, in term of coefficient of variation and reproducibility, with 600 nM of mt primers, 300 nM of nuclear primers, 250 nM of each probes and 1 ng of DNA per reaction. We performed the experiment on the automated droplet generator and reader from Bio-rad (QX200 system) in 20 μL reactions.

**Plasmid system.** In order to verify whether the two fluorescent dyes present different intensities of fluorescence emission and to normalize for differences between runs (master mix performance, instrument calibration, environmental variability, etc.) a plasmid construct was designed. A portion of mt-tRNA\textsubscript{Leu} and B2M genes were amplified using the previously reported primers. Two sequential TA cloning reactions were performed to insert the two targets into the pGEM-T vector (Promega Co., Madison, WI, USA). The successful cloning of the two target sequences in a 1:1 ratio was verified by sequencing and PCR. The distance between both inserts was chosen to be greater than 500 bp to avoid the amplification of both targets as one amplicon in the qPCR reaction (Fig. 1).

Plasmids were extracted from NEB Turbo Competent E. coli (New England Biolabs, Ipswich, MA, USA) with PureYield Plasmid Midi prep kit (Promega Co., Madison, WI, USA) and the concentration was measured using Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). The plasmid was linearized by Scal digestion (New England Biolabs, Ipswich, MA, USA) and the linearized plasmid was used as calibrator in all the qPCR experiments.

**Amplification efficiencies.** A range of experiments was carried out to test the efficiencies of the PCR reactions. Several serial dilutions of a DNA template and of the plasmid, linear as well as circular, diluted in water or in low-TE (10 mM Tris-HCl and 0.1 mM EDTA) + LPA (Linear Polyacrylamide, 20 µg/ml) were generated to
obtain standard curves and determine PCR efficiency (E). PCR efficiency was calculated from the slope of the standard curves using the equation formula: 

\[ E = 10^{-\frac{1}{slope}} - 1 \]

In order to improve the precision, all reactions for the standard curves were performed in quadruplicates.

**mtDNA copy number calculation.**

Relative quantification was applied to calculate the copy number of mtDNA per diploid nuclear (2n) cell:

\[ 2 \times 10^{-\Delta \Delta Cq} \]

In Equation (1): “Cq” is the quantification cycle, \( \Delta \Delta Cq \) is \( (Cq_{mt} - Cq_{nuc})_{sample} - (Cq_{mt} - Cq_{nuc})_{plasmid} \) “E” is the averaged mean efficiency of the PCR reactions of the two targets and “2” is to account for the two copies of nDNA in a cell. The mtDNA copy number values were calculated from all three replicates and the mean value was used for downstream analysis. The standard deviation of the \( \Delta Cq \) values among the three replicates was assessed for both targets. Around 5% of the samples had a coefficient of variation (CV) >2% within the triplet reactions and therefore they were excluded from the analysis.

**Inverted probes experiment.**

To confirm that neither probe sequence nor primer affinity differences could have affected the assay, we performed a validation experiment using the same protocol and primer pairs but inverted labelled probes: B2M FAM-5′-CAGGTTGCTCCACAGGTAGCTCTAG-BHQ1 and mt-tRNA Leu Y akima Yellow -5′-TTACCGGGCTCTGCCATCT-BHQ1. Efficiencies and \( \Delta Cq \) were assessed for the plasmid and for a DNA template using standard curves as described above.

A comparison of 88 samples measured with both probe combinations was carried out.

**Probe batch effect.** A comparison experiment between two different probes and primers batches (same sequences and dyes) was carried out. Efficiencies and \( \Delta Cq \) values were assessed for the plasmid and for a DNA template using standard curves. A comparison of 88 samples measured with both probe sets was performed in order to evaluate the correction effect of the plasmid.

**mtDNA copy number accuracy.** To evaluate the inter-assay variability a positive control was included in eight independent experiments together with the plasmid. The mtDNA copy numbers of the sample were calculated for the eight plates measured on different days using the \( \Delta Cq_{plasmid} \) to correct the values obtained.

**Statistical analysis.** Statistical analyses were performed using RStudio with R 3.2.3 (Vienna, Austria, http://www.R-project.org) and Microsoft Excel (Microsoft Corporation, Redmond, WA). Non-normally distributed data were compared using nonparametric tests (Friedman test and Spearman rank correlation coefficient). A P value ≤ 0.05 was considered statistically significant.

**Results**

The efficiency of the assay design was assessed by serial dilutions of DNA standards and of plasmid DNA. The amplification efficiencies obtained from the standard curves were approximately 100% for both targets within the DNA templates (Fig. 2A) as well as within the plasmid (Fig. 2B). All efficiencies comprised values between 94% and 100% with a mean value of 96%.
The standard curves of the calibrator plasmid revealed that the FAM dye emission signal exceeded the Yellow (YY) signal even though both targets were present in a 1:1 ratio on the same plasmid. This resulted in a \( \Delta C_q \) value between FAM and YY probe of up to 1.8 cycles, which would correspond to a 3.5-fold different amount of molecules. Since this difference is caused technically by the differing fluorescence intensities rather than by real difference in target copy number, we subtracted the plasmid \( \Delta C_q \), i.e. \((C_{q\text{mitochondrial}} - C_{q\text{nuclear}})_{\text{plasmid}}\), from each sample.

It has been described by others that using the linearized form of the plasmid is advantageous compared to the circular one. Therefore, we compared the amplification curves of the circular versus the linearized form of the plasmid. No efficiency differences were identified but an average shift in the \( C_q \) values of 1.65 \( \pm \) 0.21 was observed. This is probably due to the supercoiled plasmid form (the dominant template species in the first cycle) and the different accessibility among the two targets. The PCR efficiency of the plasmid suspended in TE + LPA was comparable to suspension in water. Due to these results we used the linearized form of the plasmid for all other experiments.

**Influence of inverted probes on stability of copy number results.** A further evaluation of the assay was performed using the standard PCR protocol with inverted labeled probes (i.e. FAM for nucDNA and YY for mtDNA). The efficiencies of the DNA template and the plasmid DNA were on average 98% and 103%. We found a change in \( \Delta C_q \) (up to 2.2 cycles) between the two probe systems, which, however, did not change the final resulting CN values, because it had been mitigated by our plasmid-based correction. A plate containing 94 samples was analyzed with both probe sets. Six samples were excluded due to high standard deviations in the triplicates. The comparison of mtDNA copy number values in 88 samples between the two probe systems showed consistent results with a strong correlation (Spearman’s \( r = 0.81, p < 2.2 \times 10^{-16} \)). Scatter plot and fitted linear regression curves are shown in Fig. 3A.

**Influence of the plasmid correction factor on the inter-assay variability and effects of probe and primer batches.** To validate high throughput screening of large cohorts, we performed a comparison between different probe and primer batches. The amplification efficiencies of a DNA template and the plasmid DNA were both on average 99–100%. When changing probe production batches, we observed a \( \Delta C_q \) change in the sample from 6.51 using the first probe batch to 5.57 using the second batch (\( \Delta C_q_{\text{batch1}} - \Delta C_q_{\text{batch2}} = 0.94 \)). A similar change was detected also in the plasmid, with a change from 1.76 to 0.82 (\( \Delta C_q_{\text{batch1}} - \Delta C_q_{\text{batch2}} = 0.92 \)). This shows that using the plasmid as a correction factor, the "batch effect" can be minimized and the accuracy of the analyses improved. A plate containing 94 samples was analyzed with both probe batches. Six samples were excluded due to high standard deviations in the triplicates. The comparison of mtDNA copy number values in 88 samples between the two probe sets showed consistent results with a good correlation (Spearman’s rho = 0.86, \( p < 2.2 \times 10^{-16} \)). Scatter plot and fitted linear regression curves are shown in Fig. 3B.

No major changes in \( \Delta C_q \) values were detected using different primer batches.

For validation of the inter-assay reproducibility one DNA template was included in each of eight independent experiments running on different days. The calculation of the mtDNA copy number was conducted with and without the use of the plasmid as a correction factor. The CVs were determined for both calculation methods. The use of the plasmid reduced the inter-assay variation from 21% (uncorrected values) to 7% (plasmid corrected value) as shown in Fig. 4.

**Influence of different isolation methods on total extractable mitochondrial genomes.** The applicability of the method for the determination of mtDNA copies in a routine epidemiological setting was evaluated using DNA samples that were isolated with different methods. 18 blood samples from 18 healthy volunteer...
donors were extracted in parallel by three different methods: EZ1 DNA Blood 200µl kit (EZ1), INVISORB Blood Universal Kit (INV) and phenol-chloroform-isoamyl alcohol extraction (PCI) as described previously.

We detected significant differences in the mtDNA-CN per 2n genome depending on the extraction methods applied (Friedman test p-value = 3.419 × 10^{-7}). The copies of mtDNA/2n averaged 39.5 ± 20 for EZ1, 283 ± 164.6 for INV and 160.4 ± 71.9 for PCI (Fig. 5). Spearman’s rho showed no significant correlation between EZ1 and PCI (Spearman’s rho = 0.14, p-value = 0.56). A moderate correlation was found between INV and PCI (Spearman’s rho = 0.52, p-value = 0.028) and INV and EZ1 (Spearman’s rho = 0.47, p-value = 0.049). A subgroup of samples (n = 52) were typed in parallel with ddPCR. We achieved an average of 16100 ± 1700 accepted droplets per sample. Three samples were excluded because of weak signal. The results showed a strong correlation between qPCR and ddPCR results (Spearman’s rho = 0.80, p = 5.47 × 10^{-12}).

A difference in quantification results depending on the extraction methods was identified also in a subsequent experiment on a larger sample size. We measured the mtDNA-CN in a cohort study of 303 probands of the FHKS study where the DNA was extracted from blood using two methods (EZ1 and INV). The measurements based on INV were higher than measurements based on EZ1, as showed in Fig. 6A. There was only a weak correlation between the two methods (Spearman’s rho = 0.14, p = 0.015). Scatter plot and fitted linear regression curves are shown in Fig. 6B.

Extractability and reproducibility of total DNA extraction using different extraction methods.

To check the intra-assay repeatability of the three different extraction methods we investigated parallel measurements on total DNA from 4 healthy donors. Each blood sample was divided in 45 identical aliquots (300µl each): 15 of them were extracted by EZ1, 15 with PureGene kit (PG) and 15 with Chelex resin.

Automated EZ1 extraction showed the lowest copy number values (averaged 63.8 mtDNA copies/2n ± 15.7), but also the smallest variability within the aliquots (average CV was 15%). Higher values and considerable variability were detected with the other two manual methods (PG 332.1 ± 130.3 and Chelex 206.5 ± 55.2 mtDNA copies/2n, average CV were 27.5% and 24.6% respectively). A representative sample is displayed in Fig. 7.

The PCR efficiencies of eight aliquots carrying the largest variability were checked by standard curves to exclude a bias in the PCR reactions such as the presence of PCR inhibitors in the sample. The PCR efficiencies were calculated from the slope of the standard curves obtained by serial dilution of the samples using the formula previously reported26. All but one of the efficiency values were in a range from 95% to 102%.

Influence of cell lysis buffer on the target accessibility.

In order to verify whether these discrepancies in the mtDNA-CN results were due to a different efficacy of cell membrane lysis techniques during the standard DNA extraction protocol (potentially resulting in unpredictable losses of mtDNA or mitochondrial particles), an experiment with four different lysis buffers was performed and the mtDNA-CN values were measured at six different incubation time points. The extractions were then completed using EZ1 DNA Tissue kit and the BioRobot EZ1 Advanced. The reference baseline for mtDNA-CN retrieved from the EZ1 tissue kit was at 41.4 copies per diploid genome. All used lysis buffers showed an increase of accessible mitochondrial genomes over time. We
reached the highest values after 72 hours of incubation with RIPA buffer used in combination with proteinase K (Fig. 8).

A subgroup of samples extracted in parallel with EZ1 Tissue kit after 72 hours of incubation with RIPA + PK and PureGene showed very close CV values (PG 16.16% vs RIPA + PK 17.48%) but no correlation (Spearman ρ = 0.1, p = 0.95).

**Discussion**

The intent of this study was to design a high-throughput assay to allow precise and reliable quantification of mtDNA-CN defined as the ratio of molecules per diploid cell. The growing interest in mtDNA-CN variations and the conflicting results in the recent literature reveal the need to establish a solid and cost-effective method for this measurement. We show that the use of a dual insert plasmid as a calibrator allows the correction against unequal emission intensities of the differently fluorescence labelled probes between different runs and improves
the accuracy of the results. This approach combined with a duplex qPCR assay does not require external standards and is easily applicable in large-scale epidemiological studies. Moreover, it allows cost reduction and an increased reproducibility of measurement while keeping the intra- and inter-assay variability low. Furthermore, our results showed a strong correlation with droplet digital PCR. Additionally, we found convincing evidence that mtDNA content measurement is strongly influenced by the DNA isolation method as already suspected by Guo et al.43. However, this previous study was limited by a low number of samples (n = 8) and only two DNA extraction methods (silica-based column and phenol-chloroform-isoamyl alcohol).

Figure 7. Chart showing mtDNA content measured in 45 identical aliquots obtained from the same blood sample extracted in parallel using three different DNA extraction methods. DNA was extracted using EZ1 DNA Blood 200µl kit (EZ1), PureGene kit (PG) and Chelex resin (CH). Higher values and considerable variability were detected with the two manual methods (INV 332.1 ± 130.3 and Chelex 206.5 ± 55.2 mtDNA copies, average CV were 27.5% and 24.6% respectively) than in the automated method EZ1 (averaged 63.8 mtDNA copies ± 15.7, average CV was 15%). The quantitative mtDNA content is shown on the y-axis.

Figure 8. Time curve showing mtDNA content measured in a blood sample extracted by BioRobot EZ1 Advanced after incubation using 4 different lysis buffers. The buffers used were G2 (included in the EZ1 Tissue kit) and Pierce RIPA Buffer Lyse (Thermo Fisher Scientific, Waltham, MA, USA). Both buffers were used pure and in combination with Proteinase K (PK). The baseline is obtained using the standard EZ1 tissue kit protocol without incubation.
In many publications qPCR approaches have been used to measure mtDNA-CN. First, the literature data are contradictory in terms of the association drawn by the particular study and second, even the real mtDNA copy number stated for a specific cell type is not reproducible among the different investigations. This lack of reproducibility across laboratories could be due to several issues such as inappropriate primers sets, dilution bias, lengths of amplicon but also – as we investigated extensively in the current study – different primer and probe batches, instrument calibration problems, different isolation procedures or variations within dye emission intensities. Our approach addressed the MIQE quality criteria. In particular, it was challenging to design specific mtDNA primers since more than 95% of the mitochondrial genome is duplicated into the nuclear genome. To our knowledge, we are the first to confirm the specificity of our mtDNA primers by ultra-deep-sequencing: a perfect alignment of all reads with a coverage of over 80,000X demonstrated the unique amplification of mitochondrial genomes and the complete absence of co-amplified “nuclear insertions of mitochondrial origin” (NUMTs).

The analysis of the plasmid quantification results showed an unexpected ΔCq among the two targets. Despite the same amount of starting copies in each plasmid (1:1 ratio, verified also by sequencing) and a perfect equality in PCR efficiencies, the two amplification curves did not overlap. This resulting ΔCq is very likely due to differences in the probe fluorescence or a bias how the probe signals are detected. An identical, in terms of magnitude, “artificial” increase in ΔCq has been observed also in the DNA samples. For this reason, we modified the standard formula for copy number calculation applying the \((C_{\text{q}}-C_{\text{q}}_{\text{plasmid}})\) to correct the \((C_{\text{q}}_{\text{nuc}}-C_{\text{q}}_{\text{plasmid}})\). Based on eight independent experiments we demonstrated that the use of the plasmid considerably reduces the inter-assay CV and therefore improved the accuracy of the analyses. This demonstrates that differences in fluorescence dye emission intensity and/or uncalibrated emission filter settings within the detection instrument are likely to occur for any used combination of dye and platform. Therefore, we strongly recommend the inclusion of a plasmid calibrator for any individually designed multiplexed qPCR assay.

During the validation process we found evidence that DNA isolation methods severely affects the measurement of mtDNA by altering the mtDNA/nDNA ratio. Significant differences in mtDNA-CN values between DNA isolation methods and no or little correlations between the different methods revealed a substantial pre-analytical bias of mtDNA-CN determination. A pronounced variability was found also within aliquots of the same blood sample extracted repeatedly with different DNA extraction methods (INV and Chelex) albeit the PCR efficiencies were constantly around 98% for all the samples. This convincingly demonstrated that the differences in the mtDNA-CN values cannot be explained by differences in qPCR efficiencies but by a strong variability of molecules present in a single aliquot probably caused by the pre-analytical steps.

In our study, the manual salting out-based methods PG and INV always resulted in the highest values but also the largest absolute and relative variability. The variability among aliquots was probably due to a problematic DNA elution step. The presence of undissolved DNA clumps could have altered the mtDNA-CN measurement. In contrast, Nacheva and colleagues found that phenol-based DNA extraction led to higher number than Puregene (salting-out method). However, they measured the copy number variation using sequencing data in fresh frozen brain samples.

Additionally, by applying Chelex extraction we recovered lower numbers of mitochondrial genomes than with the salting-out approach although this method does not require any washing step and should therefore represent the real mtDNA/nDNA ratio within a cell. Using EZ1 as representative of a magnetic bead-based extraction, we obtained the lowest values together with the smallest absolute and relative variability among aliquots. It is known that longer DNA fragments are better retrieved during the magnetic bead-based DNA extraction, therefore we assume that the beads preferentially bind nuclear DNA as compared to the smaller mtDNA, which is more easily lost during the washing steps. Moreover, automated EZ1 extraction procedure led to higher reproducibility of the results compared to manual methods. This was probably due to the manual handling procedure.

Furthermore, the DNA extraction process of mtDNA may be impeded compared to nuclear DNA due to the fact that the molecules are surrounded by a double bilayer where one of them incorporates extensive invaginations as compared to the bilayer of the nucleus. DNA samples incubated at different time points with different lysis buffers indicated that a more aggressive buffer combined with a longer incubation allowed the retrieval of a larger numbers of mtDNA molecules. We therefore conclude that mtDNA-CN values measured might not reflect the precise biological ratio. With the currently available extraction protocols, it might well be that neither a complete extraction of total mtDNA nor a precise biologically representative ratio of both types of DNA molecules is feasible. Based on these findings it is essential that automated extraction protocols with low aliquot variability should be used for mtDNA-CN studies. Furthermore, it is crucial that all samples are processed under the same conditions and only one type of DNA extraction method must be used within a study cohort or in studies between different cohorts. This should be applied to prevent artificial associations based on different extraction methods between the two observed study groups rather than due to real associations. Similar observations have been made recently by our group in a study that revealed different association with relative telomere length measurements depending on the DNA extraction method applied. Low numbers of mtDNA copies that might not be representative for the real mtDNA-CN such as we experienced with EZ1 could result in false negative results. Hence, missing a biological difference between two groups can be overcome by increasing the sample size which might at least in part compensate a larger measurement error.

In conclusion, we developed an accurate assay for mitochondrial copy number detection including a plasmid for correction of the intra-assay and inter-assay variability. Furthermore, we discovered that the different DNA extraction methods selectively isolate different amounts of the two types of DNA molecules in a sample. It is therefore crucial to take into account these differences before performing a comparative mitochondrial copy number study. To have reproducible and reliable results, an automated extraction method is strongly recommended and the same protocol should be followed in the entire study.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Fernández-Silva, P., Enriquez, J. A. & Montoya, J. Replication and Transcription of Mammalian Mitochondrial Dna. Exp. Physiol. 88, 41–56 (2003).
2. Clay Montier, L. L., Deng, J. J. & Bai, Y. Number matters: control of mammalian mitochondrial DNA copy number. J. Genet. Genomics 36, 125–131 (2009).
3. Robin, E. D. & Wong, R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J. Cell. Physiol. 136, 507–513 (1988).
4. Malik, A. N. & Czajka, A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion 13, 481–492 (2013).
5. Melser, S., Lavie, J. & Bénard, G. Mitochondrial degradation and energy metabolism. Biochimica et Biophysica Acta - Molecular Cell Research 1853, 2812–2821 (2015).
6. Rooney, J. P. et al. In Mitochondrial Regulation: Methods and Protocols (eds. Palmeira, C. M. & Rolo, A. F.) 1241, 23–38 (Springer New York, 2015).
7. Whitaker, R. M. et al. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury. Kidney Int. 88, 1336–1344 (2015).
8. Kilbaugh, T. J. et al. Peripheral blood mitochondrial DNA as a biomarker of cerebral mitochondrial dysfunction following traumatic brain injury in a porcine model. PLoS One 10, 1–16 (2015).
9. Hesgood, H. D. et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis 31, 847–849 (2010).
10. Fernández-Galilea, M. et al. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1851, 273–281 (2015).
11. Pyle, A. et al. Reduced mitochondrial DNA copy number is a biomarker of Parkinson’s disease. Neurobiol. Aging 38, 216.e7–216.e10 (2015).
12. Bai, R.-K. et al. Mitochondrial DNA content varies with pathological characteristics of breast cancer. J. Oncol. 2011, 496189 (2011).
13. Mengel-From, J. et al. Mitochondrial DNA copy number in peripheral blood cells declines with age and is associated with general health among elderly. Hum. Genet. 133, 1149–1159 (2014).
14. Barrientos, A. et al. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Mol. Brain Res. 52, 284–289 (1997).
15. Tin, A. et al. Association between Mitochondrial DNA Copy Number inPeripheral Blood and Incident CKD in the Atherosclerosis Risk in Communities Study. J. Am. Soc. Nephrol. 27, 2467–2473 (2016).
16. Wong, J. et al. Mitochondrial DNA content in peripheral blood monocytes: Relationship with age of diabetes onset and diabetic complications. Diabetologia 52, 1953–1961 (2009).
17. Xu, F. X., Zhou, X., Shen, F., Pang, R. & Liu, S. M. Decreased peripheral blood mitochondrial DNA content is related to HbA1c, fasting plasma glucose level and age of onset in Type 2 diabetes mellitus. Diabet. Med. 29, 47–54 (2012).
18. Xia, P. et al. Decreased mitochondrial DNA copy numbers in blood samples of patients with stage 1 breast cancer. BMC Cancer 9, 454 (2009).
19. Andreu, A. L., Martinez, R., Martí, R. & García-Arumí, E. Quantification of mitochondrial DNA copy number: Pre-analytical factors. Mitochondrion 9, 242–246 (2009).
20. Nacheva, E. et al. DNA isolation protocol effects on nuclear DNA analysis by microarrays, droplet digital PCR, and whole genome sequencing, and on mitochondrial DNA copy number estimation. PLoS One 12, e0180467 (2017).
21. Sims, D., Sudbery, I., Iott, N. E., Heger, A. & Ponting, C. P. Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15, 121–132 (2014).
22. Ashar, F. et al. Association of mitochondrial DNA levels with frailty and all-cause mortality. J. Mol. Med. 93, 177–186 (2014).
23. Memon, A. A. et al. Quantification of mitochondrial DNA copy number in suspected cancer patients by a well optimized ddPCR method. Biomol. Detect. Quantif. 13, 32–39 (2017).
24. van Heesch, S. et al. Systematic biases in DNA copy number originate from non-template procedures. Genome Biol. 14, R33 (2013).
25. Diskin, S. J. et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 36, 1–12 (2008).
26. Bustin, S. A. et al. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin. Chem. 55, 611–622 (2009).
27. Kolacsek, O. et al. Ct shift: A novel and accurate real-time PCR quantification model for direct comparison of different nucleic acid sequences and its application for transposon quantifications. Gene 598, 43–49 (2017).
28. Charrier, S. et al. Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther. 18, 479–487 (2011).
29. Phillips, N. R. et al. Simultaneous quantification of mitochondrial DNA copy number and deletion ratio: a multiplex real-time PCR assay. Sci. Rep. 4, 3887 (2014).
30. Titze, S. et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: Composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol. Dial. Transplant. 30, 441–451 (2015).
31. Raschenberger, J. et al. Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study. Atherosclerosis 242, 529–534 (2015).
32. Frattini, V. et al. A metabolic function of FGFFR3-TACC3 gene fusions in cancer. Nature 553, 222–227 (2018).
33. Jackson, C. B., Gallati, S. & Schaller, A. QPCR-based mitochondrial DNA quantification: Influence of template DNA fragmentation on accuracy. Biochem. Biophys. Res. Commun. 423, 441–447 (2012).
34. Malik, A. N., Shahni, R., Rodríguez-de-Ledesma, A., Laftah, A. & Cunningham, P. Mitochondrial DNA as a non-invasive biomarker: Accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem. Biophys. Res. Commun. 412, 1–7 (2011).
35. Lott, M. Y. et al. In Current Protocols in Bioinformatics 44, 1.23.1–1.23.26 (John Wiley & Sons, Inc., 2013).
36. Physiur, K. et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: prevalence of the mutation in an adult population. Am. J. Hum. Genet. 63, 447–454 (1998).
37. Ye, J. et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13, 134 (2012).
38. Weissensteiner, H. et al. mtDNA-Server: next-generation sequencing data analysis of human mitochondrial DNA in the cloud. Nucleic Acids Res. 44, W64–9 (2016).
39. Bai, R.-K. & Wong, L.-J. C. Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease. J. Mol. Diagn. 7, 613–22 (2005).
40. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101–1108 (2008).
41. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, 45e–45 (2001).
42. Hou, Y. et al. Serious overestimation in quantitative PCR by circular (supercoiled) plasmid standard: microalgal pcna as the model gene. *PLoS One* **5**, e9545 (2010).
43. Guo, W., Jiang, L., Bhasin, S., Khan, S. M. & Swerdlow, R. H. DNA extraction procedures meaningfully influence qPCR-based mtDNA copy number determination. *Mitochondrion* **9**, 261–265 (2009).
44. Côté, H. C. F. et al. Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. *Mitochondrion* **11**, 520–7 (2011).
45. Bordelon, H., Russ, P. K., Wright, D. W., Haselton, F. R. & Dillen, P. W. A Magnetic Bead-Based Method for Concentrating DNA from Human Urine for Downstream Detection. *PLoS One* **8**, e68369 (2013).
46. Raschenberger, J. et al. Influence of DNA extraction methods on relative telomere length measurements and its impact on epidemiological studies. *Sci. Rep.* **6**, 25398 (2016).

**Acknowledgements**
This study was supported by the transnational doctoral program BI-DOC between the Innsbruck Medical University, Austria and the Institute of Biomedicine, Eurac, in Bolzano; by the Austrian Research Fund (FWF, W-1253 DK HOROS); and by the Oesterreichische Krebshilfe (Projekt Nr. 15009).

**Author Contributions**
F.F. performed the lab experiments, the statistical analysis and wrote the first draft of the manuscript, L.F. supervised the project and the lab experiments, F.K. and S.C. provided valuable scientific discussion, B.S. and M.B. contributed valuable experimental work. All authors, including A.A.H., contributed in finalizing and reviewing the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2018